Use mouse models to test existing and investigational drugs for Alzheimer's; focus on drug repositioning and combo therapy development.
Funding for Alzheimer's drug development from pre-clinical to Phase I clinical trials to prevent, slow, or treat AD symptoms, excluding basic research and non-pharmacological interventions.
NIH supports genome editing and other biologic therapies for Alzheimer's disease-related dementias, from lead optimization and drug development through safety studies and early clinical evaluation.
This grant supports academic and biotech researchers in developing new drugs to prevent, slow, or treat Alzheimer’s disease through preclinical and early-stage clinical research.
Drug Development RFP supports researchers and clinicians developing drugs and devices through IND-enabling studies and early clinical trials to advance treatments for Alzheimer’s disease and related dementias.
Prevention RFP - Alzheimer's Drug Discovery Foundation supports researchers and clinicians conducting human studies of targeted interventions, combination therapies, and drug choices to reduce dementia risk.